Peptides on Instagram: what Colombia, Guatemala and Mexico flagged

From trend to health alert

Peptides are no longer a niche topic. In November 2025 the AP described unapproved peptide injections as a new fad among wellness influencers, fitness trainers and celebrities⁶. The promises range from fat loss and muscle recovery to anti-aging²⁶. A 2026 review describes how digital promotion and gray-market access normalize products of uncertain identity, purity and sterility⁹. In 2026 regulators in the region responded.

Colombia: the full list

On June 24, 2026 INVIMA published Health Alert 184-2026. It named, one by one, products sold through an Instagram account and a website: DSIP, Selank, Semax, PT-141, ipamorelin, CJC-1295 without DAC, BPC-157, GHK-Cu, TB-500 and retatrutide¹. INVIMA called them fraudulent, unregistered products that "have not been evaluated in terms of quality, safety or efficacy"¹.

It is probably the official list closest to what people search for today when they type "peptides" into social media. Several of those names also appear on the World Anti-Doping Agency's 2026 Prohibited List: BPC-157 as a non-approved substance; ipamorelin, CJC-1295 and TB-500 among peptide hormones, growth factors and related substances¹³.

Guatemala: the Central American precedent

In August 2026 Guatemala's Ministry of Public Health warned that unregistered injectable peptides are being sold illegally, with products promoted online to burn fat, build muscle, boost performance or rejuvenate². According to the report, the ministry stressed that every person has the right to know exactly what is being sold and injected into them².

Mexico and PAHO: the GLP-1s

In March 2026 Cofepris warned about tirzepatide and other weight-loss products sold without registration on "e-commerce platforms, websites and mobile apps"³. Days earlier, on 27 February, PAHO had published a regional epidemiological alert on GLP-1 misuse, publicized on 3 March, warning about sales through unofficial channels, including the internet and social media⁴. Social media amplifies the trend: in a 2026 analysis of the 400 most popular TikTok videos on semaglutide and tirzepatide, 98% came from individual users or influencers, with lower reliability scores than content from health professionals¹⁰.

What about Panama?

As of this writing we found no MINSA alert aimed at peptides such as BPC-157 or TB-500. There is a precedent: in May 2024 the DNFD relayed an INVIMA alert on semaglutide-plus-B12 vials not registered in Panama and warned about sales online, on social media and WhatsApp⁵. In other words, the DNFD has already taken Colombian alerts and reissued them locally⁵.

Both sides of the debate

Promoters of these peptides point to animal studies and personal experience⁶. Regulators point to the lack of quality, safety and efficacy evaluation, and to the fact that buyers cannot verify what is in the vial¹². When researchers bought semaglutide from illegal online pharmacies, the vials' measured purity was 7.7–14.4%, against 99% on the label, and all contained endotoxin⁸. For BPC-157, the FDA flags possible immunogenicity and peptide-related impurities; for the thymosin beta-4 fragment, it found no human exposure data¹⁴. A 2026 sports medicine review adds that rigorous human safety data are scarce and that social media amplifies the placebo effect¹¹. And in a small 2026 study, 20 untrained adults relying only on internet information correctly completed 15 of 34 steps when trying to prepare a gray-market product¹². Both sides agree that demand exists and is growing; the argument is over who answers for product quality¹²⁶.